Objective. To elucidate the role of hypoxia and inflammatory pathways in the pathogenesis of iatrogenic laryngotracheal stenosis (iLTS). Study Design. (1) Examination of mucosal surface gene expression in human iLTS. (2) In vitro comparison of normal and scar laryngotracheal fibroblasts under normoxic and hypoxic conditions.
L aryngotracheal stenosis is a fibrotic disease that leads to luminal narrowing of the larynx and/or trachea and may cause significant respiratory distress. 1 Iatrogenic laryngotracheal stenosis (iLTS) is the most common etiology and can affect .10% of critically ill patients after endotracheal intubation. 1, 2 The mechanisms leading to iLTS are unknown, but may involve an abnormal wound-healing response similar to other fibrotic diseases. 3 The initial intubation injury can cause inflammation, which leads to fibroblast differentiation, proliferation, and formation of a pathologic scar. [4] [5] [6] Few investigations into the pathogenesis of iLTS have focused on fibroblasts and myofibroblasts, the end effector cells in many diseases of fibrosis. 7 Myofibroblasts can be derived from fibroblasts, are rarely found in normal tissue, and possess a distinct profibrotic phenotype that combines contractility with extracellular matrix (ECM) deposition. 8 Recent studies have shown that when compared with normal fibroblasts, fibroblasts isolated from laryngotracheal scar proliferate faster, exhibit metabolic changes, and express more collagen. 9 This echoes the profibrotic phenotype observed in other organs. In cardiac fibrosis, fibroblasts transdifferentiate into myofibroblasts in response to ischemic injury, producing excessive ECM and a contracted scar. 10 Similarly, hepatic cirrhosis and idiopathic pulmonary fibrosis involve the transdifferentiation of hepatic stellate cells and pulmonary fibroblasts into myofibroblasts. 11, 12 Within these in vitro models from the heart, liver, lungs, and skin, a severe 1%-3% O 2 hypoxic environment promotes the shift toward a myofibroblast phenotype, resulting in increased fibroblast proliferation and ECM production. [13] [14] [15] [16] A few studies have explored the role of hypoxia in the pathogenesis of iLTS. Clinical experience shows that cuff pressure and endotracheal tube friction can both contribute to tracheal injury. 17 This initial trauma can cause local tissue ischemia, especially in the critically ill and hypoperfused patient. 2, 18 In prospective studies, severe respiratory failure and high cuff pressure correlated highly with tracheal injury. 19 As the injury heals, local tissue may become even more hypoxic. Studies from hypertrophic skin scars show that oxygen tension in the skin during scar formation may be \10% of the baseline in normal skin. 20 In animal models of iLTS, piglets displayed histologic signs of injury after 4 hours of intubation, and hypoxic ventilation significantly increased the severity of this injury. 21 Yet despite the in vitro evidence from parallel fibrotic diseases in other organs, there has not been adequate investigation into the effect of hypoxia on laryngotracheal fibroblasts. Given the suspected mechanisms for local tracheal injury and ischemia, we hypothesize that hypoxia will promote a transdifferentiation of normal laryngotracheal fibroblasts into myofibroblasts and help maintain the increased proliferation and ECM production observed in scar fibroblasts. 9 We aim to first define the surface gene expression profile of laryngotracheal scar in one set of patients, and then test our hypothesis of myofibroblast transdifferentiation through an in vitro model, with fibroblast cell lines isolated from a separate set of iLTS patients.
Methods

Subject Recruitment
Informed written consent was obtained from all participants in accordance with the Johns Hopkins University Institutional Review Board (NA_00078310). All patients had a diagnosis of iLTS and received operative treatment from the senior author (A.T.H.) between August 2012 and June 2016.
Extraction of RNA from Human Brush Biopsy Samples
Surface brush biopsies were obtained in the operating room from normal and scarred portions of the larynx and trachea of 9 iLTS patients with the use of a ConMed Disposable Bronchial Cytology Brush (Utica, NY), visualized under direct laryngoscopy. All normal and scarred sites in the trachea were at least 2 cm apart. Brush samples were homogenized, and RNA was extracted with the AllPrep RNA/Protein Kit (Qiagen, Valencia, California). RNA quantification, cDNA synthesis, and quantitative real-time polymerase chain reaction (qRT-PCR) were conducted through technical triplicates.
Fibroblast Isolation and Culture
Tissue biopsies were subsequently taken from normal and scarred portions of the subglottis or trachea in 8 patients with iLTS (different from the brush biopsy group). Fibroblasts were cultured and expanded. 22 After reaching P5-8, fibroblast cell lines were trypsinized, split, and grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% GlutaMax, 1% NEAA, and 5% penicillin/streptomycin (all from Gibco, Waltham, Massachusetts) under either normoxic or hypoxic conditions. Normoxic cultures were incubated at 37°C in a humidified 5% CO 2 / 95% air incubator. Hypoxic cultures were incubated in a modular, sealed, humidified chamber (Billups-Rothenberg, Inc, Del Mar, California) containing 1% O 2 / 5% CO 2 / 94% N 2 at 37°C; gas inside the chamber was replaced every 24 hours.
Cell Proliferation and Cell Count
Fibroblasts in normoxic and hypoxic conditions were seeded onto 6-well culture plates (Falcon; BD Biosciences, Tewksbury, Massachusetts) at 5 3 10 3 cells per well. Cells were trypsinized and counted with a hemocytometer daily, over 6 days. All proliferation experiments were conducted in biological duplicates.
Gene Expression Analysis by qRT-PCR
Fibroblasts in normoxic and hypoxic conditions were seeded onto 6-well culture plates (Falcon) at 2.5 3 10 5 cells per well. Cells were trypsinized after 12 and 48 hours. All in vitro gene expression experiments were conducted in biological triplicates. RNA was extracted with RNAeasy Micro Kits (Qiagen). cDNA was synthesized with the iScript cDNA synthesis kit (BioRad, Hercules, California). qRT-PCR was performed and monitored with SYBR Green PCR Mastermix (Applied Biosystems, Foster City, California) on the StepOnePlus Real Time PCR System (Applied Biosystems). Reaction mixtures were incubated for 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C, 1 minute at 60°C, and 15 seconds at 95°C. ACTB was used as the reference gene. Target genes of interest included the fibrosis markers MMP13 (matrix metalloproteinase 13), COL1 (collagen 1), aSMA (alpha smooth muscle actin), FN1 (fibronectin 1), and COL3 (collagen 3), as well as the inflammatory markers IL-6 (interleukin 6) and TGF-b (tumor growth factor beta). All primers are available upon request. 9
Protein Expression Analysis by Western Blot
Fibroblasts in normoxic and hypoxic conditions were seeded onto T25 culture plates (Falcon) at 1 3 10 6 cells per plate. Cells were trypsinized after 12 and 48 hours. Protein was extracted with a lysis buffer consisting of RIPA buffer (50mM Tris-HCL, 150mM NaCl, 2% NP-40, 1% Na deoxycholate, 0.2% SDS), 10mM PMSF, 50mM EGTA, 10mM Na orthovanadate, 0.5mM Na fluoride, 1% cOmplete Protease Inhibitor Cocktail (Sigma-Aldrich, St Louis, Missouri), and deionized water. Proteins (20 mg) were resolved on NuPAGE 4%-12% Bis-Tris gel (Life Technologies, Carlsbad, California) in NuPAGE MOPS SDS Running Buffer (Life Technologies) and transferred onto a PVDF membrane (Bio-Rad, Hercules, California) with the NuPAGE Transfer Buffer (Life Technologies). The membrane was blocked for 1 hour with 5% bovine serum albumin (Sigma) in Tris-buffered saline with 0.1% Tween (TBST), incubated at 4°C overnight with the primary antibody in TBST, washed, and finally incubated for 1 hour with the secondary antibody in TBST. Antibody concentrations were as follows: 1°mouse anti-GAPDH (Abcam, Cambridge, Massachusetts), 1:3000; 1°rabbit anti-aSMA (Abcam), 1:200; 2°goat anti-mouse (Abcam), 1:5000; 2°goat anti-rabbit (Cell Signaling, Danvers, Massachusetts), 1:4000. Bands were visualized with the ECL Prime chemiluminescence system (Amersham, Freiburg, Germany) and detected with the BioSpectrum Imaging System (UVP, Upland, California).
Statistical Analysis
Cell proliferation results are expressed as the mean difference between groups 6 95% CI. The mean difference in cell growth on each day was compared between conditions (hypoxic vs normoxic) with a multilevel mixed effects model in Stata 12 (StataCorp, College Station, Texas). 23 Relative gene expression was calculated with the delta cycle threshold (dCT) method. In qRT-PCR, the cycle threshold (CT) value is defined as the number of cycles required for the fluorescent signal emitted by DNA amplification to cross a standard threshold. The dCT measures the amount of target DNA in the sample relative to the reference gene ACTB. dCT was thus defined as CT Target -CT Reference , and delta dCT (ddCT) was defined as dCT Hypoxic -dCT Normoxic . Fold change between hypoxic and normoxic conditions was calculated as 2 -ddCT . 24 dCT values between normoxic and hypoxic conditions were compared with a multilevel mixed effects model in STATA12. Statistically significance was defined as a P value \.05.
Results
Human Laryngotracheal Scar Displays Increased Expression of IL-6, aSMA, and MMP13 vs Normal Tracheal Mucosa
Demographic and clinical information for the surface brush biopsy iLTS patients (n = 9) is displayed in Table 1 . All surface brush biopsy iLTS patients were adults. Surface brush biopsies taken from scarred areas of the trachea showed significantly higher expression of IL-6 (fold change = 2.8, P \ .01, 95% CI: 1.4-3.9), aSMA (fold change = 3.0, P = .01, 95% CI: 1.2-3.9), and MMP13 (fold change = 5.4, P = .02, 95% CI: 1.2-6.3) versus normal areas (Figure 1 ). There were no significant differences in expression of COL1 (fold change = 8.8, P = .50, 95% CI: 0.3-10.3) and TGF-b (fold change = 1.4, P = .20, 95% CI: 0.7-1.9) between normal laryngotracheal tissue and scar.
Fibroblasts Isolated from Normal Tracheal Mucosa Proliferate Faster under Hypoxic Conditions
Demographic and clinical information for the iLTS patients (n = 8) who donated fibroblast cell lines is displayed in Table 2 . All iLTS cell line donors were adult patients. Cell proliferation of fibroblasts isolated from normal portions of trachea was compared under normoxic and hypoxic conditions ( Figure 2) . Fibroblasts proliferated significantly faster under hypoxic conditions on all 6 days of incubation (P \ .01 each day).
Fibroblasts Isolated from Normal Trachea Show
Increased Expression of IL-6, COL1, aSMA, and MMP13 under Hypoxic Conditions Gene expression of fibroblast cell lines isolated from normal trachea was compared under normoxic and hypoxic conditions (Figure 3a) . After 12 hours in hypoxia, fibroblasts showed significantly increased expression of IL-6 (fold change = 2.6, P \ .01, 95% CI: 1.2-3.2). After 48 hours in hypoxia, fibroblasts showed significantly increased expression of aSMA (fold change = 2.0, P = .03, 95% CI: 1.0-2.7), COL1 (fold change = 1.1, P = .03, 95% CI: 1.0-1.3), and MMP13 (fold change = 1.6, P = .01, 95% CI: 1.1-2.0). TGF-b was significantly decreased after 48 hours under hypoxia (fold change = 0.9, P \ .01, 95% CI: 0.8-0.9). At 48 hours under hypoxia, fibroblasts also showed increased protein expression of aSMA (Figure 3b ).
Fibroblasts Isolated from Scarred Trachea Also
Proliferate Faster under Hypoxic Conditions, but Do Not Show Changes in IL-6, COL1, or aSMA Expression Fibroblasts isolated from laryngotracheal scar (in the same 8 iLTS patients) also displayed significantly faster proliferation under hypoxic conditions as compared with normoxic conditions (6 days of incubation, P \ .02 each day; Figure 4 ). However, scar fibroblasts did not develop the same expression profile as normal fibroblasts when subjected to hypoxic conditions ( Figure 5 ). TGF-b was significantly decreased after 48 hours under hypoxia (fold change = 0.9, P = .01, 95% CI: 0.8-1.0). No differences in IL-6, MMP13, COL1, aSMA, COL3, or FN1 expression were observed at any of the time points.
Discussion
This is the first study that examines the effect of hypoxia on laryngotracheal fibroblasts and its role in the formation of tracheal scar. Our results lead to several unique perspectives on the pathogenesis of iLTS. While similarities between iLTS and other diseases of fibrosis have always been suspected, this is the first study that demonstrates a myofibroblast phenotype in iLTS scar. Using an in vitro model, we show that hypoxia influences both the initiation and the maintenance of a profibrotic phenotype and that these changes may be mediated by inflammatory pathways involving IL-6. Through our brush biopsies, we demonstrate that the surface cells of laryngotracheal scar display a myofibroblast phenotype. Myofibroblasts can be transdifferentiated from resident fibroblasts and are defined by the molecular marker aSMA, a protein that gives them twice the contractile force of undifferentiated fibroblasts. 25 Under conditions of pathologic fibrosis, dysregulated myofibroblasts lay down an abundance of collagens and other ECM proteins. 26 Matrix metalloproteinases may also be excessively produced, modifying and maintaining the ECM secreted by myofibroblasts. 27 Specifically, upregulation of MMP13 has been shown to play a dysfunctional role in the pathogenesis of idiopathic pulmonary fibrosis. 28 With increased expression of aSMA, MMP13, and COL1, our scar brush biopsy results indicate an increased presence of myofibroblasts and a profibrotic phenotype similar to other diseases of fibrosis.
With a better understanding of the differences between healthy mucosa and laryngotracheal scar, we aimed to use an in vitro model to explore the role of hypoxia in this phenotypic change. As studies in other organs have used severely hypoxic environments (1% O 2 ) to induce the transdifferentiation of fibroblasts into myofibroblasts, 13, 14 we expected a similar phenotypic shift in tracheal fibroblasts. Our findings show that when normal tracheal fibroblasts are subjected to hypoxic conditions, they undergo a significant increase in aSMA expression, marking a shift toward a myofibroblast phenotype. We also observe a significant increase in the rate of cell proliferation and significant upregulation of other profibrotic markers, including MMP13 and COL1. Taken together, these findings support the hypothesis that hypoxia may play a role in the initial phase of iLTS, setting off a cascade of events that includes transdifferentiation of resident tracheal fibroblasts into myofibroblasts and the shift toward a profibrotic phenotype. This is consistent with in vivo studies of hypertrophic scars, which show a severely decreased oxygen tension during the proliferative phase of scar formation. 20 Our findings also suggest that this phenotypic shift may be related to activation of IL-6, a cytokine involved in hypoxic and profibrotic pathways. In cardiac myocytes, IL-6 expression can be induced by hypoxic stimulation. 29 In keloid fibroblasts, IL-6 expression is significantly higher than in nonlesional fibroblasts, and inhibition of IL-6 signaling leads to a decrease in ECM production. 30 In our brush biopsy experiments, IL-6 expression in iLTS scar is significantly higher that that of healthy tissue. In our in vitro experiments, we show that a hypoxic environment leads to a similar upregulation of IL-6 after 12 hours. Interestingly, these inflammatory changes in IL-6 precede the transdifferentiation of fibroblasts into myofibroblasts, which does not occur until 48 hours under hypoxia. While our results do not prove a causative relationship between IL-6 upregulation and myofibroblast transdifferentiation, we do observe a temporal relationship between the 2 events. This temporal relationship, along with the evidence from other organs, suggests that IL-6 activation may be crucial to the common phenotype observed in fibrotic diseases.
Hypoxia continues to drive increased cell proliferation in tracheal scar but does not cause the same myofibroblast shift seen in normal fibroblasts. One explanation for this observation is that the fibroblasts isolated from tracheal scar already contain a large population of myofibroblasts. This is evidenced by the significantly increased aSMA expression seen in our scar brush biopsy samples. Thus, hypoxia appears to play a differential role in the formation and maintenance of tracheal scar. This is also consistent with in vivo studies of hypertrophic scars, which suggests that the low oxygen tension observed in early scar returns to normal in mature scars. 20 Once the scar matures, hypoxia no longer appears to drive the inflammatory microenvironment and fibroblast phenotype, but it does continue to induce the hyperproliferation of fibroblasts. The sustained elevation that we observe in cell proliferation under hypoxic conditions may be supported by metabolic adaptations in stressed fibroblasts, which include a lower rate of oxidative phosphorylation and reduced mitochondrial mass. 31 This allows fibroblasts to shift energy production from an oxygendependent pathway to an oxygen-independent pathway, creating the Warburg-like effect that we previously described in our scar fibroblasts. 9 Our findings open the door to a few therapeutic considerations. Hyperbaric oxygen therapy can increase partial oxygen pressure in tissues to address hypoxia, and it has been shown to reduce fibrosis after tracheal resection. 32 However, more studies are required to better understand the therapeutic effect of hyperbaric oxygen therapy in the initial phase of tracheal stenosis, when hypoxia appears to have the largest influence on fibroblast transdifferentiation. From an inflammatory standpoint, a humanized antibody to the IL-6 receptor, tocilizumab, has shown early success for the treatment of skin fibrosis. 33 Further animal studies and clinical trials are needed to clarify the therapeutic potential of IL-6 inhibitors in iLTS.
Surprisingly, normal and scar tracheal fibroblasts both showed a significant downregulation of the profibrotic cytokine TGF-b under hypoxia. Other studies are equivocal; some show that TGF-b stimulation of fibroblasts can lead to transdifferentiation into myofibroblasts, 34 while others show that TGF-b production is not increased in fibroblasts under hypoxia. 35 In chronically hypoxic wounds, TGF-b signaling pathways may be downregulated, 36 suggesting negative feedback mechanisms between hypoxia-and TGF-b-induced downstream targets. Future studies may better delineate the interaction between these 2 signaling pathways.
Although our in vitro model is widely used in other organs, it does not fully simulate the inflammatory microenvironment observed in vivo. By focusing on fibroblasts, we are able to isolate the effect of hypoxia on these end effector cells in iLTS. However, we cannot comment on how other cytokines and immune cells interact with hypoxia. 3, 5 Evidence from other organs suggests that hypoxia can also lead to increased secretion of myofibroblast activating cytokines from epithelial cells. 37 Contributions from other cell types may be explored in future in vitro coculture experiments.
Finally, we recognize that while our results point to a role for hypoxia in the formation and maintenance of laryngotracheal scar, hypoxia is not likely the sole contributing factor in the pathogenesis of iLTS. As other studies have suggested, additional contributing factors include microbiome shifts in the larynx and trachea 38 and the ensuing perichondritis after hypoxic injury caused by intubation. 39 Recent discoveries also highlight the potential for a genetic predisposition to laryngotracheal scar formation; one study found an association between a polymorphism in MMP1 and the formation of scar after intubation injury. 40 This discovery complements our finding of elevated matrix metalloproteinase activity after hypoxic stimulation of normal laryngotracheal fibroblasts, suggesting that genetic predisposition may enhance the effects of hypoxia on the laryngotracheal ECM. Ultimately, we believe that iLTS is multifactorial disease arising from a combination of genetic predisposition, hypoxic and mechanical tissue injury, and subsequent consequences on local microbiome and inflammation. Future studies are required to better understand the interaction among these mechanisms and how they all come together to lead to the formation of laryngotracheal scar.
Conclusion
Human iLTS scar displays a myofibroblast phenotype, which includes upregulation of aSMA and other profibrotic ECM proteins. Under hypoxic conditions in vitro, fibroblasts isolated from normal trachea hyperproliferate and transdifferentiate into a similar myofibroblast phenotype. This transdifferentiation may be mediated by the fibrosis cytokine IL-6. Fibroblasts from tracheal scar do not display the same transdifferentiation but do display hyperproliferation. These results elucidate the differential role of hypoxia in the formation and maintenance of tracheal scar.
